ClinicalTrials.gg
Active, not recruitingNCT04711109BRCA-PUpdated Oct 5, 2026

Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation

A Phase 3 interventional study of Denosumab and Placebo in BRCA1 Mutation, Breast Cancer and Breast Diseases, sponsored by Alliance for Clinical Trials in Oncology. Active, not recruiting at 47 sites in United States. Open to female participants aged 25 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Alliance for Clinical Trials in Oncology · Phase 3, Interventional, and Prevention

How we know

Updated Oct 5, 2026Sponsor changed1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
25 Years to 55 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 24 studies testing denosumab in Breast Neoplasms — none open to participants now, 3 under way, 2 of them phase 3. Denosumab · Breast Neoplasms.

Planned enrollment
5th of 24
300 · median 53
Started
2023
the only one that year
Phase 3
9 of 24
none open now
Registered
24th of 24
by date
Lead sponsor
1 of 24
Alliance for Clinical Trials in Oncology

Among the 24 studies testing denosumab in Breast Neoplasms, this one is the 5th largest by planned enrollment, is the only one that started in 2023, is one of 9 in phase 3, and was the 24th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

None of the 24 studies testing denosumab in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →

About denosumab

Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 25 Years to 55 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 24 studies testing denosumab in Breast Neoplasms as a file.
02

Study summary

This phase III trial compares denosumab to placebo for the prevention of breast cancer in women with a BRCA1 germline mutation. A germline mutation is an inherited gene change which, in the BRCA1 gene, is associated with an increased risk of breast and other cancers. Denosumab is a monoclonal antibody that is used to treat bone loss in order to reduce the risk of bone fractures in healthy people, and to reduce new bone growths in cancer patients whose cancer has spread to their bones. Research has shown that denosumab may also reduce the risk of developing breast cancer in women carrying a BRCA1 germline mutation.

Read the detailed description

PRIMARY OBJECTIVE:

I. To evaluate the reduction in the risk of any breast cancer (invasive or ductal carcinoma in situ [DCIS]) in women with germline BRCA1 mutation who are treated with denosumab compared to placebo.

SECONDARY OBJECTIVES:

I. To determine the reduction in the risk of invasive breast cancer in women with germline BRCA1 mutation who are treated with denosumab compared to placebo.

II. To determine the reduction in the risk of invasive triple negative breast cancer (TNBC) in women with germline BRCA1 mutation who are treated with denosumab compared to placebo.

III. To determine the reduction in risk of ovarian, fallopian and peritoneal cancers (in women who have not undergone prophylactic bilateral salpingo-oophorectomy [PBSO]) in women with germline BRCA1 mutation who are treated with denosumab compared to placebo.

IV. To determine the reduction in risk of other (i.e. non-breast and nonovarian) malignancies, including those known to be associated with BRCA1 germline mutations in women with germline BRCA1 mutation who are treated with denosumab compared to placebo.

V. To determine the reduction in the risk of clinical fractures in pre- and postmenopausal women with germline BRCA1 mutation who are treated with denosumab compared to placebo.

VI. To compare rates of breast biopsies and rate of benign breast lesions in women with germline BRCA1 mutation who are treated with denosumab compared to placebo.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM A: Patients receive denosumab subcutaneously (SC) every 6 months (q6m) for up to 5 years in the absence of the development of breast cancer or unacceptable toxicity.

ARM B: Patients receive placebo SC q6m for up to 5 years in the absence of the development of breast cancer.

After completion of study treatment, patients are followed up every 12 months for 5 years.

03

Conditions studied

  • BRCA1 Mutation
  • Breast Cancer
  • Breast Diseases
  • Breast Neoplasms
  • Breast Carcinoma
  • Neoplasms

Keywords

  • RANKL
  • Breast Cancer Prevention
  • Denosumab
  • Bone Density Conservation Agents
  • Physiological Effects of Drugs
04

Who can participate

Ages eligible
25 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women with a confirmed deleterious or likely deleterious BRCA 1 germline mutation (variant class 4 or 5)
  • Age >= 25 years and =\< 55 years at randomization
  • No evidence of breast cancer by MRI or mammography (MG) and clinical breast examination within the last 6 months prior to randomization
  • No clinical evidence of ovarian cancer at randomization
  • Negative pregnancy test at randomization for women of
  • No preventive breast surgery planned at time of randomization
  • (ECOG) performance status of 0 or 1
  • Written before any study-specific procedure is performed

Exclusion criteria

Exclusion Criteria:

  • Prior bilateral mastectomy
  • History of ovarian cancer (including fallopian and peritoneal cancer)
  • History of breast cancer
  • History of invasive cancer except for basal cell or squamous cell skin cancer or carcinoma in situ of the cervix, stage 1 papillary or follicular thyroid cancer, atypical hyperplasia or LCIS (lobular carcinoma in situ)
  • Pregnant or lactating women (within the last 2 months prior to randomization)
  • Unwillingness to use highly effective method during and within at least 5 months after cessation of denosumab/placebo therapy in women of . (Note: Women of childbearing potential should be monitored for pregnancy prior to each denosumab/placebo injection)
  • hypocalcemia (history and current condition), or serum calcium \< 2.0 mmol/L (\< 8.0 mg/dL)

    * Hypocalcemia defined by calcium below the normal range (a single value below the normal range does not necessarily constitute hypocalcemia, but should be 'corrected' before dosing the subject). Monitoring of calcium level in regular intervals (usually prior to product [IP] administration) is highly recommended

  • Tamoxifen, raloxifene or aromatase inhibitor use during the last 3 months prior to randomization or for a duration of more than 3 years in total (current and prior hormone replacement therapy [HRT] is permitted)
  • Prior use of denosumab
  • Subject has a known prior history or current evidence of osteonecrosis or osteomyelitis of the jaw, or an active dental/jaw condition which requires oral surgery including tooth extraction within 3 months of enrollment
  • Concurrent treatment with a bisphosphonate or an anti-angiogenic agent
  • Any major medical or psychiatric condition that may prevent the subject from completing the study
  • Known active infection with virus or virus
  • Known infection with (HIV)
  • Use of any other investigational product (current or prior aspirin or non-steroidal anti-inflammatory drugs [NSAIDs] are permitted)
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Arm A (denosumab)

    Patients receive denosumab SC q6m for up to 5 years in the absence of disease progression or unacceptable toxicity.

    Drug: Denosumab · Other: Quality-of-Life Assessment

  • Placebo comparator
    Arm B (placebo)

    Patients receive placebo SC q6m for up to 5 years in the absence of disease progression.

    Drug: Placebo · Other: Quality-of-Life Assessment

Interventions

  • Given SC

  • DrugPlacebo

    Given SC

  • OtherQuality-of-Life Assessment

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Time to the occurrence of any breast cancer (invasive or ductal carcinoma in situ [DCIS])

    Time to breast cancer (invasive or DCIS) will be compared between the two treatment arms using a stratified Cox proportional hazards regression model.

    Time frame: From randomization to the occurrence of breast cancer (invasive or DCIS), assessed up to 5 years

Secondary outcomes

  1. Time to invasive breast cancer

    Will be compared between the two treatment arms using a stratified Cox proportional hazards regression model.

    Time frame: Up to 5 years post treatment

  2. Time to invasive triple negative breast cancer

    Will be compared between the two treatment arms using a stratified Cox proportional hazards regression model.

    Time frame: Up to 5 years post treatment

  3. Time to ovarian, fallopian and peritoneal cancer (in women who have not undergone prophylactic bilateral salpingo-oophorectomy)

    Will be compared between the two treatment arms using a stratified Cox proportional hazards regression model. Time to ovarian cancer will be analyzed in the overall group and in different strata (oral contraceptive use, hormone replacement therapy use, and menopausal status).

    Time frame: Up to 5 years post treatment

  4. Time to other (nonbreast or ovarian cancer) malignancies, including those known to be associated with BRCA1 mutations

    Will be compared between the two treatment arms using a stratified Cox proportional hazards regression model.

    Time frame: Up to 5 years post treatment

  5. Time to clinical fractures in pre- and postmenopausal women

    Will be compared between the two treatment arms using a stratified Cox proportional hazards regression model.

    Time frame: Up to 5 years post treatment

  6. Frequency of breast biopsies

    May be recommended as part of care based on a finding on mammogram, MRI, ultrasound or physical exam performed as part of monitoring for breast cancer. Will be compared between the two treatment arms via chi-square analysis.

    Time frame: Up to 5 years post treatment

  7. Frequency of benign breast lesions

    May be recommended as part of care based on a finding on mammogram, MRI, ultrasound or physical exam performed as part of monitoring for breast cancer. Will be compared between the two treatment arms via chi-square analysis.

    Time frame: Up to 5 years post treatment

  8. Assess incidence, nature and severity of adverse events (AEs) using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0

    Overall toxicity rates (percentages) for grade 3 or higher adverse events considered at least possibly related to treatment will be reported per treatment arm.

    Time frame: Up to 5 years post treatment

07

Study locations

47 sites
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Jul 2027, 53 months after the start.

Of 328 non-industry phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 127. This study's planned 53 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2021
First posted
Jan 15, 2021
StartActual
Feb 14, 2023
Primary completionEst.
Jul 2027
CompletionEst.
Dec 2033
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • MedStar Georgetown University Hospital · Washington D.C., United States
Show 1 removed
  • MedStar Georgetown University Hospital · Washington, United States
Oct 5, 2026
Sponsor
Collaborators added: Austrian Breast & Colorectal Cancer Study Group; collaborators removed: Austrian Breast & Colorectal Cancer Study Group (ABCSG)
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    1 site added, 1 site removed
    Show site
    • MedStar Georgetown University Hospital · Washington D.C., United States
    Show 1 removed
    • MedStar Georgetown University Hospital · Washington, United States
    Sponsor Collaborators added: Austrian Breast & Colorectal Cancer Study Group; collaborators removed: Austrian Breast & Colorectal Cancer Study Group (ABCSG)
    + 3 other changes: index terms, identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04711109
Collaborators
National Cancer Institute (NCI), Austrian Breast & Colorectal Cancer Study Group
Responsible party
Sponsor
First posted
Jan 15, 2021
Start date
Feb 14, 2023
Primary completion
Jul 2027 (estimated)
Completion
Dec 2033 (estimated)
Last update
Oct 5, 2026

Study contacts

Judy E. Garber, MD, MPH
study chair · Dana-Farber Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion